CN100518741C - 用于治疗中枢神经系统功能紊乱的孕烷类固醇 - Google Patents

用于治疗中枢神经系统功能紊乱的孕烷类固醇 Download PDF

Info

Publication number
CN100518741C
CN100518741C CNB028262751A CN02826275A CN100518741C CN 100518741 C CN100518741 C CN 100518741C CN B028262751 A CNB028262751 A CN B028262751A CN 02826275 A CN02826275 A CN 02826275A CN 100518741 C CN100518741 C CN 100518741C
Authority
CN
China
Prior art keywords
pregnane
hydroxy
steroids
steroid
stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028262751A
Other languages
English (en)
Chinese (zh)
Other versions
CN1607954A (zh
Inventor
T·贝克斯特伦
P·伦格伦
王明德
I·-M·约翰松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Umecrine AB
Original Assignee
Umecrine AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine AB filed Critical Umecrine AB
Publication of CN1607954A publication Critical patent/CN1607954A/zh
Application granted granted Critical
Publication of CN100518741C publication Critical patent/CN100518741C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028262751A 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇 Expired - Fee Related CN100518741C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0104423A SE0104423D0 (sv) 2001-12-27 2001-12-27 Pregnane steroids and their use in the treatment of CNS disorders
SE01044239 2001-12-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNA2009101459536A Division CN101601674A (zh) 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇
CNA2009101459540A Division CN101601675A (zh) 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇

Publications (2)

Publication Number Publication Date
CN1607954A CN1607954A (zh) 2005-04-20
CN100518741C true CN100518741C (zh) 2009-07-29

Family

ID=20286518

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB028262751A Expired - Fee Related CN100518741C (zh) 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇
CNA2009101459540A Pending CN101601675A (zh) 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇
CNA2009101459536A Pending CN101601674A (zh) 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2009101459540A Pending CN101601675A (zh) 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇
CNA2009101459536A Pending CN101601674A (zh) 2001-12-27 2002-12-20 用于治疗中枢神经系统功能紊乱的孕烷类固醇

Country Status (10)

Country Link
US (2) US7960367B2 (enExample)
EP (2) EP1458399B1 (enExample)
JP (2) JP2005519893A (enExample)
CN (3) CN100518741C (enExample)
AU (3) AU2002359202C1 (enExample)
CA (1) CA2468248C (enExample)
DK (1) DK1458399T3 (enExample)
ES (1) ES2394639T3 (enExample)
SE (1) SE0104423D0 (enExample)
WO (1) WO2003059357A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4914368B2 (ja) * 2004-11-18 2012-04-11 ウメクライン アーベー Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用
RU2413516C2 (ru) * 2004-11-18 2011-03-10 Умекрин Аб Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
PL2711371T3 (pl) 2006-11-21 2018-06-29 Asarina Pharma Ab Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
WO2011087441A1 (en) 2010-01-14 2011-07-21 Umecrine Mood Ab A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
US10150793B2 (en) * 2011-05-20 2018-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonists of CB1 receptor
HRP20170503T1 (hr) 2012-11-28 2017-06-16 Institut National De La Santé Et De La Recherche Médicale (Inserm) 3-(4'-supstituirani)-benzil-eter derivati pregnenolona
ME03351B (me) * 2014-01-29 2019-10-20 Umecrine Cognition Ab Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
RS67063B1 (sr) * 2017-01-09 2025-08-29 Relmada Therapeutics Inc Injektabilne suspenzije
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
AU2018218823B2 (en) 2017-02-10 2022-12-22 Relmada Therapeutics, Inc. 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
RU2020130861A (ru) 2018-04-05 2022-05-05 Асарина Фарма Апс Антагонисты гамка для применения в лечении расстройств отмены психоактивного вещества
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
WO2023083979A1 (en) * 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
US20240383941A1 (en) 2021-11-10 2024-11-21 Umecrine Ab 3-alpha substituted 3-beta-hydroxy-17-oximated androstane compound for modulation of the alpha-3 subtype of the gabaa receptor
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021977A1 (en) * 1998-10-13 2000-04-20 American Home Products Corporation Pregnane glucuronides
CN1254283A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 孕烷－3－醇－20－酮
CN1254342A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 用作孕激素和治疗CNS疾病的5α－孕烷－3β,16α－二醇－20－酮3－硫酸酯的可药用盐
CN1255141A (zh) * 1997-05-02 2000-05-31 美国家用产品公司 具有孕激素活性的5α－孕－16－烯－3β－醇－20－酮3－硫酸酯的盐
CN1300219A (zh) * 1998-03-11 2001-06-20 托布乔恩·贝克斯托罗姆 表别孕烷醇酮用于治疗cns疾病

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5439900A (en) * 1993-02-25 1995-08-08 Bukusoglu; Cuneyt Methods and compositions for providing analgesia and enhanced anesthesia
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1254283A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 孕烷－3－醇－20－酮
CN1254342A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 用作孕激素和治疗CNS疾病的5α－孕烷－3β,16α－二醇－20－酮3－硫酸酯的可药用盐
CN1255141A (zh) * 1997-05-02 2000-05-31 美国家用产品公司 具有孕激素活性的5α－孕－16－烯－3β－醇－20－酮3－硫酸酯的盐
CN1300219A (zh) * 1998-03-11 2001-06-20 托布乔恩·贝克斯托罗姆 表别孕烷醇酮用于治疗cns疾病
WO2000021977A1 (en) * 1998-10-13 2000-04-20 American Home Products Corporation Pregnane glucuronides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
'Potentiation of muscimol-induced long-term depression bybenzodiazepines and prevention or reversal byPregnenolone sulfate. AKHONDZADEH S. ET AL.PHARMACOLOGICAL RESEARCH,Vol.38 No.6. 1998 *

Also Published As

Publication number Publication date
US8119619B2 (en) 2012-02-21
AU2009201956A2 (en) 2010-02-18
JP5289281B2 (ja) 2013-09-11
JP2010065052A (ja) 2010-03-25
CA2468248C (en) 2011-08-16
EP2275109A2 (en) 2011-01-19
CA2468248A1 (en) 2003-07-24
EP2275109A3 (en) 2011-10-12
EP2275109B1 (en) 2013-07-24
SE0104423D0 (sv) 2001-12-27
CN101601674A (zh) 2009-12-16
ES2394639T3 (es) 2013-02-04
CN1607954A (zh) 2005-04-20
EP1458399A1 (en) 2004-09-22
EP1458399B1 (en) 2012-08-08
WO2003059357A1 (en) 2003-07-24
AU2009201956A1 (en) 2009-06-11
US7960367B2 (en) 2011-06-14
AU2002359202A1 (en) 2003-07-30
AU2002359202B2 (en) 2009-02-19
AU2002359202C1 (en) 2011-03-31
US20110098259A1 (en) 2011-04-28
CN101601675A (zh) 2009-12-16
AU2009201956B2 (en) 2010-11-25
AU2009201951A1 (en) 2009-06-04
DK1458399T3 (da) 2012-11-12
JP2005519893A (ja) 2005-07-07
US20050222099A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
CN100518741C (zh) 用于治疗中枢神经系统功能紊乱的孕烷类固醇
CN1270718C (zh) 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
JP2013523683A5 (enExample)
SG184111A1 (en) Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis
KR20090067198A (ko) 자궁내막 증식을 억제하는 조성물과 방법
US20120225853A1 (en) Hormone replacement therapy and depression
US8372824B2 (en) GABA-steroid antagonists and their use for the treatment of CNS disorders
RU2413516C2 (ru) Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
TW200950788A (en) Compositions and methods for male contraception
JP2003502270A (ja) ２１−ヒドロキシ−６，１９−オキシドプロゲステロン（２１ｏｈ−６ｏｐ）、及びそれのグルココルチコイド過剰を治療する薬剤としての使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090729

Termination date: 20141220

EXPY Termination of patent right or utility model